A run of half-year updates dominated the health and bio space, with recurring revenue growth and improving margins the common thread across diagnostics and digital health names. The standout corporate event came from RTW Biotech Opportunities, which crystallised a 3.7x return as portfolio company Yarrow Bioscience went public through a Nasdaq merger, while Hemogenyx Pharmaceuticals struck a hospital partnership in Lithuania for its CAR-T therapy even as its shares slipped.
RTW banks 3.7x return as Yarrow lists on Nasdaq
Yarrow Bioscience has gone public through a merger with VYNE Therapeutics, giving backer RTW Biotech Opportunities a 3.7x return on its original investment in the thyroid disease specialist. The deal marks a successful exit route for RTW's venture portfolio and puts Yarrow's pipeline in front of a broader set of Nasdaq investors as a listed entity.
Diaceutics reports 75% ARR growth in H1 update
Diaceutics (DXRX) said recurring revenue grew 75% in the first half, with churn falling sharply and forward revenue visibility now at a record level. The company said this pipeline underpins confidence in its full-year targets, with shares up 4.348% to 132.0p on the update.
Hemogenyx signs Lithuania hospital deal for CAR-T therapy
Hemogenyx Pharmaceuticals (HEMO) has agreed a Letter of Intent with Vilnius University Hospital Santaros Klinikos to research and administer its FLT3-directed CAR-T therapy HG-CT-1, using Lithuania's hospital exemption framework to fast-track clinical use ahead of full regulatory approval. The agreement gives Hemogenyx a route to patient data and treatment experience in Europe, though the shares fell 7.219% to 649.0p.
Imaging Biometrics swings to profit in first half
Imaging Biometrics (IBAI) moved into profit for the first half, a milestone chief executive Trevor Brown called "a decisive first step". Brown said converting the company's clinical momentum into recurring revenue "is our central priority for the second half and beyond", with shares trading at 0.6p.
Abingdon Health turns EBITDA positive as revenue climbs 31%
Abingdon Health (ABDX) grew revenue 31% and confirmed it turned EBITDA positive in the second half, with the rapid diagnostics developer guiding full-year revenue of £11.3m for FY26 and flagging further growth into FY27. The shares rose 4.061% to 10.25p on the update.
Kooth lifts adjusted EBITDA in first half
Kooth (KOO) reported a jump in adjusted EBITDA for the first half, with chief executive Kate Newhouse pointing to registrations "continuing to grow as we embed into the State's healthcare and educational systems". Despite the improved profitability, shares eased 2.23% to 153.5p.
Allergy Therapeutics guides to double-digit growth ahead
Allergy Therapeutics (AGY) guided toward double-digit growth after strengthening its balance sheet, with new secured funding from Hayfin providing what the company described as "a robust foundation from which to pursue our strategic growth initiatives". The shares gained 2.23% to 5.5p.
